{"product_id":"tars-bcg-matrix","title":"(TARS) Tarsus Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Tarsus Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXDEMVY 0.25%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXDEMVY 0.25% is Tarsus Pharmaceuticals, Inc.’s first approved and only commercial product, launched after FDA approval in 2023 for Demodex blepharitis. By end-2025, it is the company’s core revenue driver and main market-share asset, so it fits the Stars cell in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemodex blepharitis franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc.'s Demodex blepharitis franchise is a clear Star: the market is still being built, so physician and patient awareness can keep rising. XDEMVY launched in 2023, so this is still early in its adoption curve, not a mature eye-care line. \u003c\/p\u003e\n\u003cp\u003eThat leaves room to win share in a large, growing eye-care category as screening improves and treatment becomes routine. Growth, not saturation, is the story here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLotilaner ophthalmic platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLotilaner is the active compound in XDEMVY, Tarsus Pharmaceuticals, Inc.’s first-in-class eye drop for Demodex blepharitis. In 2025, the product’s launched base gives Tarsus a real ocular-parasitic platform, not just one brand.\u003c\/p\u003e\n\u003cp\u003eThe mechanism is differentiated because it targets parasitic mites in the eye, which supports broader eye-care expansion. That makes Lotilaner a Star in the BCG Matrix if growth stays high and XDEMVY keeps scaling.\u003c\/p\u003e\n\u003cp\u003eIts value is strategic: one compound, one approved product, and a path to follow-on ocular uses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. specialty eye-care commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. has moved from R\u0026amp;D into U.S. specialty eye-care commercialization, led by XDEMVY, which delivered about $76.6 million of net product revenue in 2024. That launch scale shows a Star profile: high-growth market, rising demand, and the need for steady promotion, pharmacy placement, and field support to keep momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net product revenue: about $76.6 million\u003c\/li\u003e\n\u003cli\u003eCommercial stage now drives growth\u003c\/li\u003e\n\u003cli\u003ePromotion and field force stay critical\u003c\/li\u003e\n\u003cli\u003ePlacement and access support expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOcular label expansion potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. is trying to widen lotilaner ophthalmic use beyond Demodex blepharitis, and meibomian gland disease is the clearest next step. XDEMVY is the first FDA-approved lotilaner eye drop at 0.25%, so a broader lid-margin and dry-eye addressable market could lift the franchise. If adoption expands, the ocular label can become a bigger growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLotilaner platform already has FDA approval\u003c\/li\u003e\n\u003cli\u003eMGD offers the main label-expansion path\u003c\/li\u003e\n\u003cli\u003eBroader use can deepen franchise value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXDEMVY Is Tarsus’ Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXDEMVY stays Tarsus Pharmaceuticals, Inc.’s Star: the only commercial product, still early in adoption, and the main growth driver. 2024 net product revenue was about $76.6 million, showing real scale but still room to expand as Demodex blepharitis screening rises.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eXDEMVY\u003c\/td\u003e\n\u003ctd\u003e$76.6M 2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTarsus Pharmaceuticals’ BCG Matrix maps its eye-care portfolio to identify Stars, Cash Cows, Question Marks, and Dogs for capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix snapshot for Tarsus Pharmaceuticals, Inc., mapping each product quadrant for quick strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTarsus Pharmaceuticals, Inc. Reference Sources provide a credible trail that speeds due diligence and supports better decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo mature cash cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, Tarsus Pharmaceuticals, Inc. still had one main commercial asset, XDEMVY, so it did not have a mature product that reliably throws off excess cash. The company is still in scale-up mode, not harvest mode. That is not a classic cash-cow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXDEMVY still in growth mode\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXDEMVY is commercial, but it is still early in its launch curve after FDA approval in 2023, so Tarsus still needs heavy marketing, education, and field support. Demodex blepharitis affects about 25 million Americans, so the addressable market is large, but awareness and conversion are still building. That means XDEMVY is not yet a passive cash cow; it is still in growth mode.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D spending remains necessary\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. is not a true cash cow yet because it still funds pipeline work and XDEMVY label expansion, so cash use stays high. Cash cows usually need little reinvestment, but Tarsus is still in build mode after its 2023 launch, with R\u0026amp;D and launch spending taking priority over near-term cash harvest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingle-product revenue base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. is still a one-product company: XDEMVY is its only marketed drug, so the revenue base is too narrow to call a true cash cow. Cash cows usually come from several mature brands with stable, repeat sales, and Tarsus has not built that cushion yet.\u003c\/p\u003e\n\u003cp\u003eThat concentration keeps cash flow tied to one launch curve, not a broad portfolio. Until Tarsus adds more approved products and durable brand depth, this stays a single-driver story, not a mature cash-cow segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital-markets dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. is still a capital-markets story, not a true cash cow. Even with XDEMVY sales building, biopharma launch costs and R\u0026amp;D keep cash generation thin, so the company still leans on outside funding and balance-sheet cash rather than surplus free cash flow.\u003c\/p\u003e\n\u003cp\u003eThat profile is the opposite of a strong Cash Cow in a BCG matrix. As of the latest 2025 filings, Tarsus still had to fund growth before it could produce durable excess cash, so capital access matters more than harvest mode.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStill funding growth, not harvesting cash\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D and launch spend pressure free cash flow\u003c\/li\u003e\n\u003cli\u003eExternal financing remains strategically important\u003c\/li\u003e\n\u003cli\u003eNot yet a classic Cash Cow profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarsus Isn’t a Cash Cow Yet: Early XDEMVY Launch Keeps Cash Flow Tied to Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. is not a classic Cash Cow as of end-2025: XDEMVY is still a young launch, and the company is still spending on sales, education, and R\u0026amp;D. With only one marketed product, cash generation is still tied to growth, not harvest. Until free cash flow turns durable and the base broadens, Cash Cow strength stays low.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed drugs\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch stage\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash cow fit\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTarsus Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Tarsus Pharmaceuticals, Inc. BCG Matrix document you'll receive after purchase. The full file is delivered with the same content, layout, and formatting shown here—no demo pages or placeholder text. Once purchased, it’s ready for immediate use in analysis, reporting, or presentations. What you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo legacy brand portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. was founded in 2016 and has no old-line mature brands in its portfolio. Its commercial story is centered on XDEMVY, so there is no low-growth legacy product to slot into the Dogs box. In BCG terms, that means the portfolio is still too young and too concentrated for a true dog asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo disclosed divestiture asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. has not disclosed any divestiture asset, so there is no named business unit to label as a classic Dog. The company has 1 main commercial product, XDEMVY, and is still focused on commercialization and pipeline expansion, which argues against shutdown or exit status. With no announced sell-off target and continued investment in growth, the Dog case stays weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTP-04 is not mature\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTP-04 is still a development program for rosacea, so it does not fit a mature, low-share Dogs label. Tarsus Pharmaceuticals reported 2024 net product revenue of $178.6 million, while TP-04 still has no approved rosacea sales, which leaves upside tied to trial and regulatory progress. That makes it closer to a Question Mark, with growth optionality rather than a weak, mature position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTP-05 is not mature\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTP-05 is aimed at Lyme disease prevention, and Lyme still drives a large unmet need: the CDC has estimated about 476,000 Americans are diagnosed and treated each year. That makes TP-05 an early, uncertain growth asset with public-health upside, not a mature low-growth product.\u003c\/p\u003e\n\u003cp\u003eBecause the program is still developing, its risk is pipeline risk, not \"dog\" risk. In BCG terms, TP-05 is better viewed as a question-mark type asset with possible long-term value if the prevention case is proven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage, not mature\u003c\/li\u003e\n\u003cli\u003ePrevention market has real unmet need\u003c\/li\u003e\n\u003cli\u003eHigh uncertainty, but upside remains\u003c\/li\u003e\n\u003cli\u003eNot a low-growth dog profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo low-growth cash trap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. has a small, concentrated portfolio, so the Dogs bucket looks light. End-2025, the Company was still driven mainly by XDEMVY, and there is no clear sign of a large, burdening laggard that would act like a low-growth cash trap. That leaves more upside assets than dog assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall portfolio\u003c\/li\u003e\n\u003cli\u003eNo clear underperformer\u003c\/li\u003e\n\u003cli\u003eMore upside than dog risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarsus: One Star, No Dogs, Growth-Led Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc. has no clear Dogs asset. In 2025, XDEMVY drove net product revenue to $178.6 million, while TP-04 and TP-05 remained precommercial, so the portfolio still looks growth-led, not like a low-share cash trap.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXDEMVY\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e$178.6M net revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-04\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eNo approved sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-05\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eNo approved sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTP-04 for rosacea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTP-04 for rosacea is still a pipeline program, so it has no revenue or market share yet. Rosacea is a large market, affecting about 415 million people worldwide and roughly 16 million in the U.S., but Tarsus has no established position there. That makes TP-04 a textbook question mark in the BCG Matrix: high market potential, low current share, and clear execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTP-05 for Lyme disease prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTP-05 sits in the Question Marks bucket because it targets Lyme disease prevention, a high-need area with no proven commercial demand yet. The U.S. sees about 476,000 Lyme disease diagnoses and treatments each year, so the market is real, but Tarsus has no TP-05 revenue base today. It still has to prove uptake, payer support, and repeat use before this can move toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTP-05 malaria reduction angle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTP-05’s malaria reduction angle adds upside, but it is still aspirational. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, so the unmet need is real, yet Tarsus Pharmaceuticals, Inc. has no commercial share to defend in this indication. That leaves TP-05 in the invest-or-exit bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMeibomian gland disease expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMeibomian gland disease expansion is a clear question mark for Tarsus Pharmaceuticals, Inc.: it extends the lotilaner platform beyond XDEMVY’s FDA-approved 2023 Demodex blepharitis use, but it still needs clinical proof and regulatory clearance. MGD drives a large dry-eye pool, with studies linking it to up to 86% of dry-eye cases, so success could open a much bigger market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew indication, not yet approved\u003c\/li\u003e\n\u003cli\u003eHigher upside than current niche\u003c\/li\u003e\n\u003cli\u003eStill development-stage risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader lotilaner life-cycle pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTarsus is trying to extend lotilaner beyond XDEMVY into eye care and dermatology, but these follow-on uses are still early and not commercially proven. That makes them classic Question Marks: high upside, but they need more capital and clear market fit before they can scale.\u003c\/p\u003e\n\u003cp\u003eIn 2025, the approved XDEMVY franchise gives the platform real clinical and commercial proof, yet the broader life-cycle pipeline still depends on new data and new demand. Without that proof, follow-on uses can stay cash-consuming rather than value-creating.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage, not yet de-risked\u003c\/li\u003e\n\u003cli\u003eNeeds funding for trials\u003c\/li\u003e\n\u003cli\u003eMust prove demand outside XDEMVY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarsus’s Question Marks: Big Markets, Thin Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTarsus Pharmaceuticals, Inc.’s Question Marks are TP-04, TP-05, and follow-on lotilaner uses: they target large unmet-need markets, but still have little or no share and no 2026 revenue proof. XDEMVY’s 2025 launch gives platform credibility, yet each new use still needs trial success, payer access, and adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-04\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eNo sales yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-05\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eDemand unproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLotilaner expansion\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eNeeds FDA\/data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235049447689,"sku":"tars-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tars-bcg-matrix.webp?v=1785733138","url":"https:\/\/dcfanalyst.com\/products\/tars-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}